Rome

• A Study to Evaluate the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s Choice of Endocrine Therapy Plus E … Ended recruitment
  2023-506821-12-00 5 2023-10-12 Estrogen Receptor (ER)-Positive, HER2-Negative, Locally Advanced or Me
• 1L LUSPA VS ESA IN NTD LOW-RISK MDS PATIENTS Ended recruitment
  2022-500430-29-00 5 2023-10-11 Myelodysplastic Syndrome (MDS)
• A study to test whether spesolimab helps people with Generalized Pustular Psoriasis (GPP) who need treatment for repeated flares Ended recruitment
  2022-502128-38-00 11 2023-10-11 Generalized Pustular Psoriasis
• A clinical study to assess how safe and effective it is for subjects with hepatocellular carcinoma (HCC) to receive radiation therapy with T … Ended recruitment
  2023-508945-41-00 4 2023-10-11 Hepatocellular Carcinoma
• Effect of study drug combined with chemotherapy in patients with locally advanced or metastatic lung cancer with mutated receptor responsibl … Ended recruitment
  2023-504434-22-00 5 2023-10-03 Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous
• A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe … Ended recruitment
  2022-501644-15-01 4 2023-09-28 Mild Cognitive Impairment due to Alzheimer's Disease Alzheimer's Disea
• Open label, long-term study evaluating safety and efficacy of subcutaneous amlitelimab in participants aged 12 years and older with moderate … Ended recruitment
  2022-502188-39-00 4 2023-09-27 Dermatitis atopic
• ELVN-002 in Solid Tumors with a HER2 Genetic Alteration Ended recruitment
  2022-502695-23-00 1 2023-09-27 Phase 1a Monotherapy Dose Escalation and Exploration: HER2 mutant, HE
• A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance T … Ended recruitment
  2022-501346-30-00 5 2023-09-25 Newly Diagnosed Multiple Myeloma with Suboptimal Response After Autolo
• Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2− Metastatic Breast Cancer Who Have Received … Ended recruitment
  2022-502593-17-00 5 2023-09-19 Locally advanced or metastatic hormone receptor (HR)-positive, human e
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer. Ended recruitment
  2022-502738-18-00 4 2023-09-15 Metastatic Non-small Cell Lung Cancer
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended recruitment
  2022-501419-15-00 5 2023-08-23 Atrial Fibrillation
• A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended recruitment
  2022-501176-26-00 5 2023-08-04 Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
• A study to test a medicine (fitusiran) injected under the skin for preventing bleeding episodes in male adolescent or adult participants wit … Ended recruitment
  2022-500221-33-01 5 2023-07-28 Hemophilia
• A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis Ended recruitment
  2024-510627-20-00 5 2023-07-28 Non-alcoholic Steatohepatitis (NASH) Cirrhosis
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatmen … Ended recruitment
  2024-513957-55-00 4 2023-07-21 Muscle invasive bladder cancer set to undergo radical cystectomy who c
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115. Ended recruitment
  2023-505643-39-00 1 2023-07-17 Spinal muscular atrophy
• A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended recruitment
  2022-501999-26-00 5 2023-07-12 Severe Hypertriglyceridemia (SHTG)
• A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com … Ended recruitment
  2022-501576-25-00 5 2023-07-07 Melanoma
• Evaluation of Long-Term Safety and Efficacy of Apitegromab in Patients with Spinal Muscular Atrophy (a genetic condition that causes muscle … Ended recruitment
  2024-511654-42-00 5 2023-06-28 Spinal Muscular Atrophy (SMA)
• A STUDY TO INVESTIGATE THE SAFETY AND EFFECTIVENESS OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY FOR PATIENTS WITH NON-SMALL CEL … Ended recruitment
  2022-502977-41-00 5 2023-06-23 Non-Small Cell Lung Cancer
• A Study to Examine the Efficacy and Safety of ZX008 in Subjects with CDKL5 Deficiency Disorder Ended recruitment
  2023-506269-78-00 5 2023-06-20 CDKL5 Deficiency disorder

Showing 1,297–1,320 of 2,096 trials